Covestor’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Covestor’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-72	Closed	-$8K	–	2829
2023 Q1	$8K	Buy	72 +69	+2,300%	+$7.94K	0.01%	1453
2022 Q4	$0	Sell	3 -3	-50%	-$195	﹤0.01%	2787
2022 Q3	$0	Sell	6 -1	-14%	-$46	﹤0.01%	2809
2022 Q2	$0	Sell	7 -2	-22%	-$58	﹤0.01%	2515
2022 Q1	$0	Buy	+9	New	+$356	﹤0.01%	2539

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Covestor's RXDX Position: Q2 2023 in Review

Covestor sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 72 shares — an estimated $8K sold.

Covestor first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $8K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Covestor reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Covestor sold 72 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $8K.
Covestor first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Covestor's Prometheus Biosciences, Inc. Common Stock position peaked at $8K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Covestor's 13F filing for Q2 2023, filed 11 Aug 2023.